HF4852
Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.
Legislative Session 94 (2025-2026)
Related bill: SF4978
Bill text versions
- Introduction PDF PDF file
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| April 07, 2026 | House | Action | Introduction and first reading, referred to | Health Finance and Policy |
Progress through the legislative process
In Committee